Catherine Tralau-Stewart

Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX.

Neusentis is a biopharmaceutical company, which is focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads. The firm is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. Icagen has two clinical stage programs in epilepsy and pain. The company was formerly known as Icagen, Inc. It was founded by Andre L. Lamotte and P. Kay Wagoner on November 23, 1992 and is headquartered in Durham, NC.

The Medical Research Council provides human healthcare and social services. It offers funding for biomedical spectrum, fundamental lab-based science, clinical trials and all major disease areas. The company was founded in 1913 and is headquartered in Swindon, the United Kingdom.

Vapogenix, Inc. operates as a clinical stage company which develops a new class of non-narcotic analgesics for localized pain. Its products are formulated volatile anesthetics; currently unformulated volatile anesthetics are used only as general anesthetics, by inhalation. The company was founded by Allen W. Burton, Phillip C. Phan and Danguole Spakevicius Altman in November 2007 and is headquartered in Houston, TX.

Babraham Bioscience Technologies Ltd. provides business research and consulting services. It also offers financial and administrative services to start-up biotech companies. The company was founded in 1996 and is located in Cambridge, UK

Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom.

The Society for Neuroscience is an organization with over 36,000 members in more than 95 countries. The non-profit company is based in Washington. The organization also engages in science advocacy and public policy, including an annual Capitol Hill Day, and has various public outreach efforts, such as the interactive collection of public-facing resources on BrainFacts.org. It was founded in 1969 and offers year-round programming, including the publication of two scientific journals, professional development resources, and career training through Neuronline.

The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012.

Biopta Ltd. provides biological research and human tissues in drug development. It conducts research on the effect of drug activity prior to clinical trials using fresh human tissues. The firm engages in the use of functional human tissue to predict drug activity prior to clinical trials. It provides lab services, comparative pharmacology, clinical biopsies, in vitro and ex vivo techniques, and customized services, as well as cardiac, vascular, respiratory, gastrointestinal, human absorption, skin, and genitourinary related services. The company was founded by David Bunton and Chris Hillier and in 2002 and is headquartered in Glasgow, the United Kingdom.

Sareum Ltd. provides drug discovery services for treatment of cancer. The company develops robust pipeline of novel small molecule cancer drug candidates for partnering with pharmaceutical companies. Sareum is headquartered in Cambridge, UK

C4X Discovery Ltd. engages in the discovery and development of medical drugs. It uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. The company was founded by Andrew Almond and Charles Douglas Blundell in January 2008 and is headquartered in Manchester, the United Kingdom.

Babraham Institute operates as charitable life sciences organization. It is a registered charity, sponsored by the Biotechnology and Biological Sciences Research Council. Babraham Institute is headquartered in Cambridge, GB.

The British Society for Immunology provides membership organization services. The non-profit company is based in London, UK.

Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom.

The British Neuroscience Association operates as a professional body that represents and promotes neuroscience and neuroscientists. The company was founded in 1960 and is headquartered in Bristol, the United Kingdom.

Helperby Therapeutics Group Ltd. engages in the development of novel solutions to treat infectious diseases with new combinations of repurposed approved drugs. The company was founded by Anthony Milnes Coates in 2002 and is headquartered in London, the United Kingdom.

PrEP Biopharm Ltd. develops and manufactures biopharmaceutical products. The British company was founded in 2015 by Ryan Muldoon and Bruce A. Malcolm. Ryan Muldoon has been the CEO since 2015.

Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom.

Revolo Biotherapeutics Ltd. develops immunologic and inflammatory medications. It develops disease resetting therapeutics for immuno-inflammatory diseases. The company was founded in 2011 and is headquartered in Stevenage, the United Kingdom.

Part of ReproCELL, Inc., ReproCELL Europe Ltd. is a British company that specializes in providing solutions for translating scientific discoveries into therapies. The company is based in Glasgow, UK. The company's expertise lies in human tissue and stem cells, and they offer consultation services to researchers facing challenges in their research. David C. Bunton has been the CEO of the company since 2017.

Dragon Finance AG specializes in corporate finance and business development. The company is based in Zurich, Switzerland. The Swiss company was founded by Dimitri F. Dimitriou.

Owkin, Inc. operates as an artificial intelligence company. It develops software which allow prediction modeling and population comparison services. The firm's products include OWKIN Socrates and OWKIN Services. The company was founded by Thomas Clozel and Gilles Wainrib in 2016 and is headquartered in Albany, NY.

Ananda Developments Plc engages in the provision of cannabinoid medicines for the treatment of complex, chronic inflammatory pain conditions. The company was founded on January 19, 2018, and is headquartered in London, the United Kingdom.

RNIB Charity is a non-profit charitable organization that provides support and advice to people with sight problems. The non-profit company is based in London, UK. The British company was founded in 2014.

EpiEndo Pharmaceuticals ehf is a clinical-stage biopharmaceutical company based in Reykjavik, Iceland. The Icelander company focuses on enhancing epithelial barrier integrity to treat inflammatory disorders, with a primary focus on chronic respiratory diseases. The company recently appointed Dr. Kate Hanrott as Director of Clinical Operations and Sciences, bringing extensive experience to the role. EpiEndo Pharmaceuticals will be attending the Bio International Convention in June 2023. EpiEndo Pharmaceuticals was founded in 2014 by Fridrik Gardarsson, and Maria Bech has been the CEO of the company since 2021.